Novozymes A/S (NVZMY) Cut to “Strong Sell” at Zacks Investment Research

Novozymes A/S (OTCMKTS:NVZMY) was downgraded by Zacks Investment Research from a “hold” rating to a “strong sell” rating in a report released on Tuesday.

According to Zacks, “Novozymes A/S is primarily engaged in the development, production, and distribution of enzymes. Its business consists of two segments, enzyme business and bio business. The Company’s enzyme business segment offers detergent enzymes that are used in laundry and dishwashing, technical enzymes used in the transformation of starch into different kinds of sugars and have application in leather, textile, and forest product industries, food enzymes used in production of bread, wine, juice, beer, noodles, alcohol, and pasta and feed enzymes used in animal feed. Its bio business segment offers microorganisms that are used in industrial and municipal wastewater treatment, as well as in the cleaning of surfaces such as carpet, concrete, drain lines, and septic tanks in industrial and household applications. It also has application in the Biopharmaceutical ingredients used in pharmaceutical industry. Novozymes A/S is headquartered in Bagsvaerd, Denmark. “

Separately, Jefferies Group reiterated a “hold” rating and set a $54.97 price target on shares of Novozymes A/S in a research report on Thursday, October 26th.

Novozymes A/S (NVZMY) opened at $49.54 on Tuesday. Novozymes A/S has a 1 year low of $37.73 and a 1 year high of $57.84. The stock has a market capitalization of $12,233.67, a price-to-earnings ratio of 30.43, a PEG ratio of 2.23 and a beta of 0.90.

Novozymes A/S (OTCMKTS:NVZMY) last issued its quarterly earnings results on Wednesday, February 7th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.46 by ($0.03). Novozymes A/S had a net margin of 21.50% and a return on equity of 29.35%. The firm had revenue of $581.18 million for the quarter. research analysts expect that Novozymes A/S will post 1.75 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Novozymes A/S (NVZMY) Cut to “Strong Sell” at Zacks Investment Research” was originally published by American Banking News and is owned by of American Banking News. If you are reading this story on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The legal version of this story can be read at https://www.americanbankingnews.com/2018/02/13/novozymes-a-s-nvzmy-cut-to-strong-sell-at-zacks-investment-research.html.

About Novozymes A/S

Novozymes A/S is a Denmark-based biotechnology company engaged in the production and sale of industrial enzymes, microorganisms and biopharmaceutical ingredients. The Company operates in four geographical regions: Europe, Middle East & Africa (including Denmark), North America, Asia Pacific and Latin America.

Get a free copy of the Zacks research report on Novozymes A/S (NVZMY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Novozymes A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novozymes A/S and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply